Table 1.
In vitro cytotoxicity of the synthesised compounds against MCF-7 and HepG2 cell lines, their VEGFR-2 inhibitory activities on cancer HepG2 cell line, and cytotoxicity for compounds 27a and 30f against normal HepG2cell line.
| Compounds | Cytotoxicity on cancer cells IC50 (µM)a |
VEGFR-2 IC50 (nM)a | Cytotoxicity on normal hepatocytes IC50 (µM)a | |
|---|---|---|---|---|
| MCF-7 | HepG2 | |||
| 27a | 7.7 | 4.5 | 3.2 | 19.94 |
| 27b | 62.3 | 41.5 | 22.5 | NT |
| 27c | 57.2 | 42.6 | 11.6 | NT |
| 27d | 30.7 | 24.1 | 21.8 | NT |
| 27e | 42.3 | 27.5 | 21.7 | NT |
| 27f | 22.7 | 19.7 | 10.7 | NT |
| 28 | 17.2 | 11.7 | 4.2 | NT |
| 29 | 23.5 | 17.5 | 9.8 | NT |
| 30a | 61.9 | 43.7 | 29.8 | NT |
| 30b | 43.8 | 34.2 | 8.7 | NT |
| 30c | 41.9 | 34.1 | 13.8 | NT |
| 30d | 42.7 | 32.4 | 15.7 | NT |
| 30e | 31.3 | 24.3 | 27.4 | NT |
| 30f | 18.1 | 10.7 | 4.9 | 15.73 |
| 30g | 61.7 | 40.8 | 38.9 | NT |
| 30h | 21.3 | 17.7 | 11.8 | NT |
| 30i | 17.2 | 12.7 | 6.1 | NT |
| 31a | 23.1 | 18.7 | 10.7 | NT |
| 31b | 19.2 | 13.7 | 5.1 | NT |
| 32 | 59.5 | 41.3 | 23.8 | NT |
| Sorafenib | 3.51 | 2.17 | 3.12 | 17.31 |
| Compound 7 | 7.2 | 4.1 | 3.4 | NT |
| Compound 8 | 4.4 | 3.3 | 3.2 | NT |
NT: not tested.
aAll IC50 values are calculated as the mean of at least three different experiments.